When first described, ESR1-e2>CCDC170 in ER+ breast cancer cells led to enhanced growth and reduced sensitivity to tamoxifen (75) suggesting a role for ESR1-e2>CCDC170 in ET resistance. The gene discussed is ESR1; the disease is breast carcinoma.